ALCAM, or CD166, is a cell adhesion molecule that mediates heterotypic cell-cell contacts via its interaction with CD6, resulting in initiation and stabilization of T-cell-dendritic-cell interactions affecting T-cell activation.
| Inventor | Institute |
|---|---|
| Carl G. Figdor | Radboud University Medical Center (UMC) |
| Cat. #: | 159675 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Immunology |
| Application: | FACS ; IP ; WB ; IP ; WB |
| Target: | Activated leukocyte cell adhesion molecule |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CD166 antigen, MEMD |
|---|---|
| Product description: | ALCAM, or CD166, is a cell adhesion molecule that mediates heterotypic cell-cell contacts via its interaction with CD6, resulting in initiation and stabilization of T-cell-dendritic-cell interactions affecting T-cell activation. It also engages in homotypic cell-cell contacts. These ALCAM-ALCAM interactions have been implicated in the development and maintenance of tissue architecture and tumor progression. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | K562-ALCAM |
| Immunogen Uniprot ID: | Q13740 |
| Target background: | ALCAM, or CD166, is a cell adhesion molecule that mediates heterotypic cell-cell contacts via its interaction with CD6, resulting in initiation and stabilization of T-cell-dendritic-cell interactions affecting T-cell activation. It also engages in homotypic cell-cell contacts. These ALCAM-ALCAM interactions have been implicated in the development and maintenance of tissue architecture and tumor progression. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Te Riet et al. 2007. J Cell Sci. 120(Pt 22):3965-76. PMID: 17971418. |
|---|
Surface expression of ALCAM on K562; K562-ALCAM; KG1a and undifferentiated MUTZ-3 cells was analyzed by flow cytometry. Unfilled histograms represent isotype control staining and shaded histograms represent staining with ALCAM antibody; AZN-L50. The mean fluorescence intensity (MFI) and percentage of positive cells are as indicated.

| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.